DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Tolerability Study of Xerecept® in Pediatric Patients

Information source: Celtic Pharma Development Services
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Brain Edema; Brain Tumor

Intervention: XERECEPT (Drug)

Phase: Phase 1/Phase 2

Status: Terminated

Sponsored by: Celtic Pharma Development Services

Official(s) and/or principal investigator(s):
Stewart Goldman, MD, Principal Investigator, Affiliation: Ann & Robert H Lurie Children's Hospital of Chicago

Summary

This study is being conducted to evaluate the safety and tolerability of Xerecept® in children with central nervous system tumors and to identify appropriate doses of Xerecept® to be used in subsequent pediatric clinical trials.

Clinical Details

Official title: A Phase I/II Open Label Individual Dose Titration Trial of the Human Corticotropin- Releasing Factor (hCRF), Corticorelin Acetate Injection (Xerecept®), to Determine the Tolerability of Xerecept® in a Pediatric Population

Study design: Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Maximum Tolerated Dose

Secondary outcome:

Dexamethasone Dosing

Incidence and severity of specified Steroid-Related Side Effects

Number of patients with adverse events

Change from baseline in clinical chemistry, hematology and urinalysis measures

PedsQLâ„¢ Quality of Life Inventory Scores

Detailed description: Steroid-related side effects are much more severe in a pediatric population than they are in adults. The side effects appear more quickly and are often apparent in as few as 14 days. Dexamethasone side effects in children include rounding of the face, acne, increased body hair, muscle weakness, osteoporosis, mood changes, weight gain, fluid retention, glucose instability, high blood pressure, increased susceptibility to infection, stunted growth and aseptic necrosis of the hip joints14-16. Although extensive studies have been performed with Xerecept® in adults, no studies have been performed with Xerecept® in pediatric subjects. Therefore, this study is being conducted to evaluate the safety and tolerability of Xerecept® in children with central nervous system tumors and to identify appropriate doses of Xerecept® to be used in subsequent pediatric clinical trials. The study will also explore if Xerecept®, when administered to pediatric patients, is effective in allowing decreases in dexamethasone dosing

Eligibility

Minimum age: 1 Year. Maximum age: 18 Years. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Have histologically confirmed primary, recurrent or metastatic cerebral tumors and require chronic steroid dosing to manage symptoms of peritumoral brain edema (No histological confirmation is required of optic pathway tumors or brain stem gliomas) 2. Have been taking dexamethasone (or equivalent) at a dose of ≥1 mg/day for a minimum of 14 days and have had a stable dose for at least 7 days. 3. Have one or more steroid-associated side effects at Screening (See Appendix A1 for a list of qualifying events) 4. Capable of self-administration of subcutaneous injections twice daily or availability of assistance from caregiver. 5. Karnofsky/Lansky performance status ≥ 40 6. Life expectancy of at least 6 months 7. Female subjects must not be pregnant or breast-feeding and, if of childbearing potential, must use adequate methods of contraception during the study 10. Ability to provide written informed consent or, if unable to provide, have a legal guardian or representative provide written informed Exclusion Criteria: 1. Evidence of previous or current overt renal, hepatic or pulmonary diseases or active uncontrolled infection 2. Subject and/or parent/guardian is unwilling or unable to comply with this protocol 3. Subject has a known history of allergy or intolerance to hCRF or other ingredients in the Xerecept® solution (e. g., methionine, mannitol) 4. Subject has a known history of hepatitis C virus, hepatitis B surface, or human immunodeficiency virus (HIV).

Locations and Contacts

Children's Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60614, United States

Dana-Farber Cancer Institute Pediatric Oncology, Boston, Massachusetts 02115, United States

Additional Information

Starting date: June 2010
Last updated: July 29, 2013

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017